요소 호기 검사 시장 규모, 점유율 및 동향 분석 보고서 : 검사 장소별, 용도별, 환자층별, 지역별 및 부문별 예측(2026-2033년)

Urea Breath Testing Market Summary

The global urea breath testing market size was valued at USD 374.13 million in 2025 and is projected to grow from USD 380.56 million in 2026 to USD 515.96 million by 2033, at a CAGR of 4.4% from 2026 to 2033. The North America urea breath testing industry held the largest share of 48.38% of the global market in 2025. The market growth is primarily driven by the rising global prevalence of Helicobacter pylori infections and associated gastrointestinal disorders, increasing preference for non-invasive and accurate gastrointestinal diagnostic technologies, and growing focus on gastric cancer prevention, early disease detection, and post-treatment monitoring. In addition, the expanding adoption of point-of-care diagnostic solutions, portable breath analyzers, and advanced 13C and 14C urea breath testing systems is further supporting global market expansion.

Global Urea Breath Testing Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global urea breath testing market report based on test location, application, patient population, and region.

• Test Location Outlook (Revenue, USD Million, 2021 - 2033)
• Hospital-based Testing
• Centralized Laboratories
• Point-of-Care Testing (POCT)
• Ambulatory Diagnostic Centers
• Application Outlook (Revenue, USD Million, 2021 - 2033)
• H. pylori Initial Diagnosis
• Post-treatment Confirmation
• Peptic Ulcer Disease Evaluation
• Gastritis Assessment
• Dyspepsia Evaluation
• Gastric Cancer Risk Monitoring
• Patient Population Outlook (Revenue, USD Million, 2021 - 2033)
• Adults
• Pediatrics
• Geriatric Population
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Spain
  • Italy
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Australia
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Test Location
  • 1.2.2. Application
  • 1.2.3. Patient Population
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline.
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Test Location Outlook
  • 2.2.2. Application Outlook
  • 2.2.3. Patient Population Outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Urea Breath Testing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook.
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising prevalence of Helicobacter pylori infections and gastrointestinal disorders
    • 3.2.1.2. Increasing preference for non-invasive and accurate gastrointestinal diagnostic technologies
    • 3.2.1.3. Growing focuses on gastric cancer prevention, early disease detection, and post-treatment monitoring
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Limited awareness and inadequate access to advanced diagnostic services in developing regions
    • 3.2.2.2. Availability of alternative diagnostic methods such as stool antigen tests, serology, endoscopy, and biopsy procedures
  • 3.2.3. Market Opportunity Analysis
    • 3.2.3.1. Growing adoption of non-invasive and point-of-care gastrointestinal diagnostics
• 3.3. Urea Breath Testing Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
  • 3.3.2. PESTEL Analysis

Chapter 4. Urea Breath Testing Market: Test Location Estimates & Trend Analysis

• 4.1. Test Location Market Share, 2025 & 2033
• 4.2. Segment Dashboard
• 4.3. Global Urea Breath Testing Market by Test Location Outlook
• 4.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 4.4.1. Hospital-based Testing
    • 4.4.1.1. Hospital-based Testing market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.2. Centralized Laboratories
    • 4.4.2.1. Centralized Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.3. Point-of-Care Testing (POCT)
    • 4.4.3.1. Point-of-Care Testing (POCT) market estimates and forecasts 2021 to 2033 (USD Million)
  • 4.4.4. Ambulatory Diagnostic Centers
    • 4.4.4.1. Ambulatory Diagnostic Centers market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 5. Urea Breath Testing Market: Application Estimates & Trend Analysis

• 5.1. Application Market Share, 2025 & 2033
• 5.2. Segment Dashboard
• 5.3. Global Urea Breath Testing Market by Application Outlook
• 5.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 5.4.1. H. pylori Initial Diagnosis
    • 5.4.1.1. H. pylori Initial Diagnosis market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.2. Post-treatment Confirmation
    • 5.4.2.1. Post-treatment Confirmation market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.3. Peptic Ulcer Disease Evaluation
    • 5.4.3.1. Peptic Ulcer Disease Evaluation market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.4. Gastritis Assessment
    • 5.4.4.1. Gastritis Assessment market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.5. Dyspepsia Evaluation
    • 5.4.5.1. Dyspepsia Evaluation market estimates and forecasts 2021 to 2033 (USD Million)
  • 5.4.6. Gastric Cancer Risk Monitoring
    • 5.4.6.1. Gastric Cancer Risk Monitoring market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 6. Urea Breath Testing Market: Patient Population Estimates & Trend Analysis

• 6.1. Patient Population Market Share, 2025 & 2033
• 6.2. Segment Dashboard
• 6.3. Global Urea Breath Testing Market by Patient Population Outlook
• 6.4. Market Size & Forecasts and Trend Analyses, 2021 to 2033 for the following
  • 6.4.1. Adults
    • 6.4.1.1. Adults market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.2. Pediatrics
    • 6.4.2.1. Pediatrics market estimates and forecasts 2021 to 2033 (USD Million)
  • 6.4.3. Geriatric Population
    • 6.4.3.1. Geriatric Population market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 7. Urea Breath Testing Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Global Regional Market Snapshot
• 7.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033
• 7.5. North America
  • 7.5.1. North America: SWOT Analysis
  • 7.5.2. U.S.
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.3. Canada
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.5.4. Mexico
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
• 7.6. Europe
  • 7.6.1. Europe: SWOT Analysis
  • 7.6.2. UK
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.3. Germany
    • 7.6.3.1. Key country dynamics
    • 7.6.3.2. Regulatory framework
    • 7.6.3.3. Competitive scenario
    • 7.6.3.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.4. France
    • 7.6.4.1. Key country dynamics
    • 7.6.4.2. Regulatory framework
    • 7.6.4.3. Competitive scenario
    • 7.6.4.4. France market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.5. Italy
    • 7.6.5.1. Key country dynamics
    • 7.6.5.2. Regulatory framework
    • 7.6.5.3. Competitive scenario
    • 7.6.5.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.6. Spain
    • 7.6.6.1. Key country dynamics
    • 7.6.6.2. Regulatory framework
    • 7.6.6.3. Competitive scenario
    • 7.6.6.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.7. Norway
    • 7.6.7.1. Key country dynamics
    • 7.6.7.2. Regulatory framework
    • 7.6.7.3. Competitive scenario
    • 7.6.7.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.8. Sweden
    • 7.6.8.1. Key country dynamics
    • 7.6.8.2. Regulatory framework
    • 7.6.8.3. Competitive scenario
    • 7.6.8.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.6.9. Denmark
    • 7.6.9.1. Key country dynamics
    • 7.6.9.2. Regulatory framework
    • 7.6.9.3. Competitive scenario
    • 7.6.9.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
• 7.7. Asia Pacific
  • 7.7.1. Asia Pacific: SWOT Analysis
  • 7.7.2. Japan
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.3. China
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. China market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.4. India
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. India market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.5. Australia
    • 7.7.5.1. Key country dynamics
    • 7.7.5.2. Regulatory framework
    • 7.7.5.3. Competitive scenario
    • 7.7.5.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.6. South Korea
    • 7.7.6.1. Key country dynamics
    • 7.7.6.2. Regulatory framework
    • 7.7.6.3. Competitive scenario
    • 7.7.6.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.7.7. Thailand
    • 7.7.7.1. Key country dynamics
    • 7.7.7.2. Regulatory framework
    • 7.7.7.3. Competitive scenario
    • 7.7.7.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
• 7.8. Latin America
  • 7.8.1. Latin America: SWOT Analysis
  • 7.8.2. Brazil
    • 7.8.2.1. Key country dynamics
    • 7.8.2.2. Regulatory framework
    • 7.8.2.3. Competitive scenario
    • 7.8.2.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.8.3. Argentina
    • 7.8.3.1. Key country dynamics
    • 7.8.3.2. Regulatory framework
    • 7.8.3.3. Competitive scenario
    • 7.8.3.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
• 7.9. MEA
  • 7.9.1. MEA: SWOT Analysis
  • 7.9.2. South Africa
    • 7.9.2.1. Key country dynamics
    • 7.9.2.2. Regulatory framework
    • 7.9.2.3. Competitive scenario
    • 7.9.2.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.3. Saudi Arabia
    • 7.9.3.1. Key country dynamics
    • 7.9.3.2. Regulatory framework
    • 7.9.3.3. Competitive scenario
    • 7.9.3.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.4. UAE
    • 7.9.4.1. Key country dynamics
    • 7.9.4.2. Regulatory framework
    • 7.9.4.3. Competitive scenario
    • 7.9.4.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
  • 7.9.5. Kuwait
    • 7.9.5.1. Key country dynamics
    • 7.9.5.2. Regulatory framework
    • 7.9.5.3. Competitive scenario
    • 7.9.5.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2025
  • 8.3.4. Thermo Fisher Scientific Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Bio-Rad Laboratories Inc.
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Sercon Group
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. Kibion GmbH
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. AdvaCare Pharma
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. AESKU.GROUP GmbH
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Kizlon Inc.
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Meridian Bioscience Inc.
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Paladin Pharma S.p.a.
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Eurofins Scientific
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives
  • 8.3.14. Beijing Richen-Force Science & Technology Co., Ltd
    • 8.3.14.1. Company overview
    • 8.3.14.2. Financial performance
    • 8.3.14.3. Product benchmarking
    • 8.3.14.4. Strategic initiatives
  • 8.3.15. Shenzhen Zhonghe Headway Bio-Sci & Tech Co. Ltd.
    • 8.3.15.1. Company overview
    • 8.3.15.2. Financial performance
    • 8.3.15.3. Product benchmarking
    • 8.3.15.4. Strategic initiatives